Denali Therapeutics Inc. DNLI Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Denali Therapeutics Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Denali Therapeutics Inc.'s accrued expenses and other liabilities?
- Denali Therapeutics Inc. (DNLI) reported accrued expenses and other liabilities of -$22.4M in Q1 2026.
- How has Denali Therapeutics Inc.'s accrued expenses and other liabilities changed year-over-year?
- Denali Therapeutics Inc.'s accrued expenses and other liabilities decreased by 131.2% year-over-year, from -$9.69M to -$22.4M.
- What is the long-term trend for Denali Therapeutics Inc.'s accrued expenses and other liabilities?
- Over 2 years (2022 to 2025), Denali Therapeutics Inc.'s accrued expenses and other liabilities has grown at a -79.4% compound annual growth rate (CAGR), from $10.92M to $465K.